Overview
Dystrophic Epidermolysis Bullosa is treated with 2 medications in our database, including VYJUVEK, ZEVASKYN. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Krystal Biotech. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Dystrophic Epidermolysis Bullosa treatment below.
FDA & Trial Timeline
10 eventsXinnate AB — PHASE2
CHU de Quebec-Universite Laval — PHASE1, PHASE2
M. Peter Marinkovich — PHASE1, PHASE2
Gang Wu, MD
M. Peter Marinkovich — PHASE1, PHASE2
Peking University Cancer Hospital & Institute
Krystal Biotech, Inc. — PHASE3
Zevaskyn: FDA approved
treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB)
Chiesi Farmaceutici S.p.A. — PHASE3
Stanford University — PHASE2
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
3 availableFilsuvez
indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older
Vyjuvek
treatment of wounds in adult and pediatric patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene
Zevaskyn
treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB)
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
2 resources3 travel grants are also available for Dystrophic epidermolysis bullosa patients — see Travel Grants below ↓
Travel Grants
3 grantsThe Assistance Fund: Epidermolysis Bullosa Financial Assistance Program
Applicants must be U.S. citizens or permanent residents diagnosed with Epidermolysis Bullosa and prescribed an FDA-approved treatment with existing coverage. Eligibility also requires meeting financial criteria based on household income and size.
Chiesi Total Care FILSUVEZ Copay Program
Community
No community posts yet. Be the first to share your experience with Dystrophic epidermolysis bullosa.
Start the conversation →Latest news about Dystrophic epidermolysis bullosa
Disease timeline:
New recruiting trial: Sirolimus DEB in Coronary Bifurcation Lesions
A new clinical trial is recruiting patients for Dystrophic epidermolysis bullosa
New recruiting trial: Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma
A new clinical trial is recruiting patients for Dystrophic epidermolysis bullosa
New recruiting trial: The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
A new clinical trial is recruiting patients for Dystrophic epidermolysis bullosa
New recruiting trial: DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
A new clinical trial is recruiting patients for Dystrophic epidermolysis bullosa
New recruiting trial: DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
A new clinical trial is recruiting patients for Dystrophic epidermolysis bullosa
New recruiting trial: DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
A new clinical trial is recruiting patients for Dystrophic epidermolysis bullosa
New recruiting trial: DEB-TACE vs cTACE in HCC After TIPS
A new clinical trial is recruiting patients for Dystrophic epidermolysis bullosa
New recruiting trial: Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
A new clinical trial is recruiting patients for Dystrophic epidermolysis bullosa
New recruiting trial: DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial
A new clinical trial is recruiting patients for Dystrophic epidermolysis bullosa
New recruiting trial: Comparison of PROVISIONal 1-stent Strategy with DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
A new clinical trial is recruiting patients for Dystrophic epidermolysis bullosa
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Dystrophic epidermolysis bullosa
What is Dystrophic epidermolysis bullosa?
Dystrophic Epidermolysis Bullosa is treated with 2 medications in our database, including VYJUVEK, ZEVASKYN. 1 of these has manufacturer assistance programs available to help reduce out-of-pocket costs. Medications are manufactured by Krystal Biotech. Patients and caregivers can find copay cards, patient assistance programs, and travel grants for Dystrophic Epidermolysis Bullosa treatment below.
Are there clinical trials for Dystrophic epidermolysis bullosa?
Yes — 20 recruiting clinical trials are currently listed for Dystrophic epidermolysis bullosa on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Dystrophic epidermolysis bullosa?
25 specialists and care centers treating Dystrophic epidermolysis bullosa are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Dystrophic epidermolysis bullosa?
2 FDA-approved treatments and 3 patient support programs are currently tracked on UniteRare for Dystrophic epidermolysis bullosa. See the treatments and support programs sections for copay assistance, eligibility, and contact details.